Diagnostic accuracy of bone metastases detection in cancer patients: Comparison between bone scintigraphy and whole-body FDG-PET

Annals of Nuclear Medicine

Volumn 20, Issue 6, 2006, Pages 399-408

  Fujimoto, Ryota ^a   Higashi, Tatsuya ^a   Nakamoto, Yuji ^a   Hara, Tadashi ^a   Lyshchik, Andrej ^a   Ishizu, Koichi ^a   Kawashima, Hidekazu ^a   Kawase, Shigeto ^a   Fujita, Toru ^a   Saga, Tsuneo ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Bone scintigraphy; FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PATIENT; CHILD; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FEMUR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LEG; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOLYSIS; PATIENT INFORMATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; TUMOR CELL; WHOLE BODY TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; WHOLE BODY IMAGING;

EID: 33747473672     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03027375     Document Type: Article

References (35)

1. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35: 84-99.
2. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23: 693-697.
3. Gendreau V, Montravers F, Philippe C, Talbot JN. Reevaluation of the usefulness of systematic bone scanning in initial staging and follow-up of small cell lung carcinoma, taking into account the serum levels of neuron-specific enolase. Int J Biol Markers 1997; 12: 148-153.
4. Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 1: S143-148.
5. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005; 35: 135-142.
6. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004; 9: 633-643.
7. Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am 2004; 42: 1123-1139.
8. Zhuang H, Kumar R, Mandel S, Alavi A. Investigation of thyroid, head, and neck cancers with PET. Radiol Clin North Am 2004; 42: 1101-1111.
9. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - usefulness and limitations in "clinical reality." Ann Nucl Med 2003; 17: 261-279.
10. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-1344.
11. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-1735.
12. 18F-FDG-PET, hexokinase-II and glucose transporter-1 expression in pancreatic cancers. J Nucl Med 2002; 43: 173-180.
13. Smith TA: FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19: 97-105.
14. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44: 317-325.
15. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-1247.
16. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005; 184: 1266-1273.
17. m-HMDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.
18. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23: 693-697.
19. 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19: 573-579.
20. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.
21. Kitano H, Magata Y, Tanaka A, Mukai T, Kuge Y, Nagatsu K, et al. Performance assessment of O-18 water purifier. Ann Nucl Med 2001; 15: 75-78.
22. 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379.
23. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer. Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-756.
24. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59: 913-918.
25. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803-809.
26. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-1247.
27. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-211.
28. Sheth H, Javed SS, Hilson AJ, Buscombe JR, Davidson BR. Radioisotope bone scans in the preoperative staging of hepatopancreatobiliary cancer. Br J Surg 2005; 92: 203-207.
29. Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001; 13: 1083-1088.
30. Nielsen OS, Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509-524.
31. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003; 28: 302-307.
32. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16: 173-180.
33. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003; 14: 1234-1240.
34. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9: 913-921.
35. Corcoran RJ, Thrall JH, Kyle RW, Kaminski RJ, Johnson MC. Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology 1976; 121 (3 Pt. 1): 663-667.